Mathematical Modelling in Forecasting the Efficiency of Treatment of Chronic Hepatitis C in Children


The study developed a model to predict the response to therapy of children with chronic hepatitis C (CHC) based on a system of multivariate analysis.

The mathematical model allows timely correction of treatment, significantly increasing the number of early virologic responses and reducing the probability of recurrence of the disease.

Aim —optimization of treatment prior to the onset of therapy with subsequent forecasting of the effectiveness of therapy based on multivariate regression analysis.

Materials and methods. The study included 116 patients at the age of 3—18 years with CHC in the replicative phase. Children with CHC were divided into 2 groups of 58 patients. Observations in children with CHC were made using clinical, biochemical, immunological and instrumental methods of research, which helped to obtain the most complete information about children with chronic viral hepatitis C. In the course of the conducted multiple regression analysis, we selected the most significant indicators for the establishment of the resulting mathematical model.

Results. The method of forecasting response to therapy in chronic hepatitis C in children developed on the basis of multivariate regression analysis and mathematical modelling of the most important immunological and biochemical parameters, is clinically efficient and justified.

Список литературы

1. Ponezheva ZhB, Semenova IV. Actual principles of therapy of chronic hepatitis of various  etiologies. Arhiv vnutrennej mediciny, 2015;(6):14—20. (In Russ.).

2. Batskikh SN. Interferon-free therapy of chronic hepatitis C: replacement of medications or new treatment paradigm? RZHGGK, 2014;(4):23—31. (In Russ.).

3. Klyarytskaya IL, Stilidi EI Serum cytokines as markers of liver fibrosis and predictors of antiviral therapy efficiency in chronic hepatitis C. KTZH, 2013;(1):93—98. (In Russ.).

4. Shapiro IYa, Sec Oк Sun, Knoring BE. Immune response and cytokine production in clinical variants of hepatocirrhosis. Med. immunol.., 2002;Vol.4(4–5): 545–552. (In Russ.).

5. Radchenko VG, Shabrov AV, Zinoviev EN. Fundamentals of clinical hepatology. Zabolevaniya pecheni i biliarnoj sistemy. Moscow, 2005:191—194. (In Russ.).

6. Romantsov MG, Sologub TV, Shuldyakov AA et al. Approaches to the treatment of liver diseases in practice of clinician. Fundamental'nye issledovaniya: Medicinskie nauki, 2011; (9):489—495. (In Russ.).

7. Larrey D, Couzigou Р, Denis J. Chronic hepatitis C: management side effects of treatment. Gastro. Clin. Biol. 2007;Vol.31(3):420–428.

8. Manns M, Wedemeyer H, Cornberg M. Treating viral hepatitis C: efficacy, side effects, and complications.  Gut. 2006;Vol.55(9):1350–1359.

9. Belousov YuB, Zyryanov SK, Afanasjeva EV Pharmacoeconomic analysis of application of protease inhibitors of hepatitis C virus. Kachestvennaya klinicheskaya praktika,  2013;(3): 22—29. (In Russ.).

10. Sapronov GV, Nikolaeva LI. New perspectives for personalized therapy in chronic viral hepatitis C. Epidemiologiya i infekcionnye bolezni, 2013;(3):27—36. (In Russ.).

11. Salman ER, Asatryan MN, Gaidarenko AD et al. Prognostic evaluation of preventable mortality associated with chronic hepatitis C. Epidemiologiya i infekcionnye bolezni, 2016;(6):40—47. (In Russ.).

Для цитирования

Churbakova OV, Рechkurov DV. Mathematical Modelling in Forecasting the Efficiency of Treatment of Chronic Hepatitis C in Children. Science & Innovations in Medicine.2017;4(8):5356.


Send an online application form to the publication